華仁藥業(300110.SZ):2020年度淨利預增113.95%-137.72%
格隆匯1月8日丨華仁藥業(300110.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨利潤9000萬元-1億元,同比增長113.95%-137.72%。業績變動原因如下:
1、隨着國內疫情得到有效控制,公司加快恢復生產和市場銷售工作,各項業務逐步恢復。
2、面對疫情期間醫療防護物資嚴重短缺的局面,公司在危機中開新局,積極佈局口罩、熔噴布、防護服等防護產品,醫療防護用品等新增業務貢獻了部分利潤。
3、報吿期內,融資規模下降,融資成本降低,利息費用相應減少。
4、疫情期間,收到政府補助較上年同期增加,歸屬上市公司股東的非經常性損益相應增加。報吿期內公司歸屬上市公司股東的非經常性損益約為740萬元。
5、報吿期內,公司收購了廣西裕源藥業有限公司、浦北縣新科藥品包裝有限公司100%股權,並於2020年11月6日辦理完畢股權轉讓的工商登記手續。根據《企業會計準則》的規定,自2020年11月起,廣西裕源藥業有限公司、浦北縣新科藥品包裝有限公司納入合併範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.